Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Vox sanguinis·2018
Same author

Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.

Vox sanguinis·2017
Same author

Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.

Vox sanguinis·2017
Same author

A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.

Vox sanguinis·2015
Same author

Pathogen inactivation of plasma components.

Vox sanguinis·2011
Same author

Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label.

Vox sanguinis·2010

Related Experiment Video

Updated: Jun 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function--an in vitro

J Irsch1, L Pinkoski, L Corash

  • 1Cerus B.V., Amersfoort, The Netherlands. jirsch@cerus.com

Vox Sanguinis
|September 2, 2009
PubMed
Summary
This summary is machine-generated.

The INTERCEPT Blood System effectively inactivates pathogens in plasma while preserving essential clotting factors for hemostasis. This pathogen inactivation (PI) technology ensures therapeutic plasma safety and function.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

Area of Science:

  • Blood product safety
  • Transfusion medicine
  • Biotechnology

Background:

  • Effective pathogen inactivation (PI) is crucial for plasma safety.
  • PI technologies must maintain haemostatic function for therapeutic use.
  • The INTERCEPT Blood System is a PI technology for plasma.

Purpose of the Study:

  • Evaluate coagulation factor functionality in INTERCEPT-treated plasma (I-FFP).
  • Assess the impact of amotosalen and UVA treatment on plasma proteins.
  • Determine if haemostatic function is retained post-treatment.

Main Methods:

  • Apheresis plasma was treated with amotosalen and UVA.
  • Plasma aliquots were analyzed before and after photochemical treatment.
  • Analysis included pro-coagulants, inhibitors, fibrinolytic proteins, contact factors, activation markers, von Willebrand complex, and complement proteins.

Main Results:

  • Procoagulant factor retention was 77-92%.
  • Von Willebrand complex components and activity were maintained.
  • Endogenous inhibitors, plasminogen, and alpha-2 antiplasmin were largely retained.
  • Coagulation activation markers remained within normal ranges, with minimal exceptions.
  • Complement activation markers (anaphylatoxins) did not increase; C1-esterase inhibitor was fully retained.

Conclusions:

  • INTERCEPT Blood System treatment preserves key haemostatic proteins in plasma.
  • The treatment does not cause inappropriate activation of coagulation, fibrinolytic, or complement pathways.
  • I-FFP maintains haemostatic function suitable for therapeutic support.